Mycobacterium tuberculosis proteins (Mtb proteins)

Mycobacterium tuberculosis proteins refers to the entire proteome of the bacterium responsible for tuberculosis, comprising approximately 4,000 distinct proteins (UniProt, 2024). These proteins are essential for the pathogen's life cycle, including cell wall synthesis, DNA replication, and energy production. Key therapeutic targets within this proteome include InhA (enoyl-ACP reductase), which is inhibited by isoniazid to disrupt mycolic acid synthesis, and RpoB (RNA polymerase beta subunit), the target of rifampicin (PubChem, 2024). Other critical targets include the F1F0-ATP synthase inhibited by bedaquiline and arabinosyltransferases inhibited by ethambutol (Nature Reviews Drug Discovery, 2021). The diversity of these proteins allows for multi-drug therapy, which is necessary to treat the infection and prevent the development of drug resistance. However, the ability of Mtb to persist in a latent state by altering its protein expression profile remains a significant challenge for drug efficacy and patient safety (NIH, 2023).

Other names

Mycobacterium tuberculosis proteomeM. tuberculosis proteinsTB proteins

Inhibition of mycolic acid biosynthesis, inhibition of DNA-directed RNA polymerase, inhibition of arabinosyltransferase, inhibition of ATP synthase, inhibition of DNA gyrase, and inhibition of protein synthesis (30S and 50S ribosome).